Wnt-activating antibodies for tissue repair
Raised to date
$76.4M
of $175M offered across 1 Form D filing
Surrozen, Inc. is a biotechnology firm headquartered in South San Francisco, California, dedicated to pioneering innovative regenerative medicines through the activation of the Wnt signaling pathway. This critical mechanism serves as a foundation for tissue repair and regeneration, positioning Surrozen at the forefront of advanced therapeutic solutions for diverse medical conditions.
Surrozen's unique focus on harnessing the Wnt signaling pathway distinguishes it from traditional approaches to regenerative medicine, providing targeted therapies for complex diseases with unmet medical needs.
| Filed | Security | Sold of offered | Filing |
|---|---|---|---|
| Apr 8, 2025 | Equity | $76.4M/ $175M | Form D |
Biologic drug
SZN-1326 is a Fzd5-targeted antibody specifically designed to treat moderate to severe ulcerative colitis by stimulating Wnt signaling in the intestinal epithelium, thereby promoting tissue repair and healing.
Built for
Healthcare providers and researchers
